Evidence map›Paper›PMID 33536752›Full record

ReviewInternational journal of chronic obstructive pulmonary disease

Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management.

René Hage, Fiorenza Gautschi, Carolin Steinack, Macé M Schuurmans

Open access · goldAbstract readReview
In one paragraph

Review in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. TFR1 as a Biomarker of Pulmonary Fibrosis Development in COPD Patients.International journal of chronic obstructive pulmonary disease · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Review
  18. Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

René HageUniversity Hospital Zurich, Division of Pulmonology, Zurich, Switzerland.ORCID 0000-0002-1994-7443
Fiorenza GautschiUniversity Hospital Zurich, Division of Pulmonology, Zurich, Switzerland.
Carolin SteinackUniversity Hospital Zurich, Division of Pulmonology, Zurich, Switzerland.
Macé M SchuurmansUniversity Hospital Zurich, Division of Pulmonology, Zurich, Switzerland.ORCID 0000-0001-5404-7566
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombined pulmonary fibrosis and emphysema (CPFE) is an underrecognized syndrome characterized by chronic, progressive disease with a dismal prognosis. Frequent co-morbidities with a higher incidence than in idiopathic pulmonary fibrosis or emphysema alone are pulmonary hypertension (WHO group 3) in 47-90% of the patients and lung cancer in 46.8% of the patients.

objectiveReview current evidence and knowledge concerning diagnosis, risk factors, disease evolution and treatment options of CPFE.

methodsWe searched studies reporting CPFE in original papers, observational studies, case reports, and meta-analyses published between 1990 and August 2020, in the PubMed, Embase, Cochrane Library, Wiley Online Library databases and Google Scholar using the search terms [CPFE], [pulmonary fibrosis] OR [IPF] AND [emphysema]. Bibliographies of retrieved articles were searched as well. Further inclusion criteria were publications in English, French, German and Italian, with reference to humans. In vitro data and animal data were not considered unless they were mentioned in studies reporting predominantly human data.

resultsBetween May 1, 1990, and September 1, 2020, we found 16 studies on CPFE from the online sources and bibliographies. A total of 890 patients are described in the literature. Although male/female ratio was not reported in all studies, the large majority of patients were male (at least 78%), most of them were current or former heavy smokers.

conclusionCPFE is a syndrome presenting with dyspnea on exertion followed by disruptive cough and recurrent exacerbations. The disease may progress rapidly, be aggravated by pulmonary hypertension WHO group 3 and is associated with an increased risk of lung cancer. Smoking and male sex are important risk factors. There is a need for more research on CPFE especially relating to etiology, influence of genetics, treatment and prevention options. Antifibrotic therapy might be an interesting treatment option for these patients.

Indexed as

EmphysemaIdiopathic Pulmonary FibrosisLung NeoplasmsPulmonary Disease, Chronic ObstructivePulmonary EmphysemaAnimalsFemaleHumansMaleRetrospective Studiesautoimmune hypothesisCOPDpulmonary hypertension

Identifiers

PMID33536752
PMCPMC7850450
OpenAlexW3123894053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.